Key Oncologics to Market Eligard™ in South Africa
Business Review Editor
Abstract
Atrix Laboratories signed an agreement providing Key Oncologics with the South African marketing rights for its Eligard™ (injectable leuprolide acetate suspension) prostate cancer products.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.